glucose bolus
Dietary Supplement50g anhydrous glucose dissolved in 300ml water consumed within 10min followed by a lunch (cheese sandwich, fruit and milk) at 4h.
NCT Number: NCT01440790
The objective of this study is to determine the effect of reducing the rate of glucose absorption on oxidative stress after eating and to compare it with the effects of vitamin C. The hypothesis is that reducing the rate of glucose absorption will reduce oxidative stress to a similar extent as 1g vitamin C.
Looking for future studies?
Notify Me18 year–75 year
All sexes
Interventional
Not applicable
Recently, much attention has been paid to evidence that abnormalities of the postprandial state (hyperglycemia) are important contributing factors to the development of chronic disease. This attention has increased interest in the role low glycemic index (GI) foods could potentially play in preventing postprandial oxidative burst/stress. GI is a means by which to categorize carbohydrate according to their postprandial glycemic response. Low GI foods promote slow intestinal absorption, prolonged and less pronounced postprandial glycemia, may decrease risk of chronic disease, as well as provide metabolic benefit to people living with glucose abnormalities as well as those with normal glucose. Few studies have been conducted looking at the potential relationship between GI and oxidation and are limited by dietary/lifestyle confounders. The proposed study has been developed to eliminate these confounders. Hypotheses (3): 1. Sipping glucose slowly over 3h will result in less oxidative stress than ingesting the same amount of glucose as a bolus over 5min. 2. Sipping glucose will reduce oxidative stress to the same extent as 1g of oral vitamin C. 3. The effect of sipping glucose on oxidative stress will occur sooner than that of vitamin C.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
50g anhydrous glucose dissolved in 300ml water consumed within 10min followed by a lunch (cheese sandwich, fruit and milk) at 4h.
50g anhydrous glucose dissolved in 300ml water consumed at rate of 25ml per 15min followed by a lunch (cheese sandwich, fruit and milk) at 4h.
50g anhydrous glucose dissolved in 300ml water consumed within 10min with 1g vitamin C followed by a lunch (cheese sandwich, fruit and milk) at 4h.
50g anhydrous glucose dissolved in 300ml water consumed at rate of 25ml per 15min. 1g vitamin C taken with first 25ml. Followed by a lunch (cheese sandwich, fruit and milk) at 4h.
Time frame: Four (4) hours after starting to eat the test meal.
Time frame: Baseline and 30, 60, 120, 180, 240, 270, 300 and 360min
Time frame: Baseline and 30, 60, 120, 180, 240, 270, 300 and 360min
Time frame: Baseline and hourly for 6h
Time frame: Baseline and 2, 4 and 6h
Time frame: Baseline and 2, 4 and 6h
Time frame: Baseline and 1, 2, 4, 5 and 6h
Time frame: Baseline and 1, 2, 4, 5 and 6h
Time frame: Baseline and 1, 2, 4, 5 and 6h
Time frame: Baseline and 1, 2, 4, 5 and 6h
Time frame: Baseline and hourly for 6hr
Time frame: Baseline and 30, 60, 120, 180, 240, 270, 300 and 360min
University of Toronto
Other
Acronym: AOGI
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT01633021
Anemia, Anemia, Hemolytic
Bethesda, Maryland, United States
View Trial DetailsNCT00469339
Breast Cancer, Breast Diseases
Houston, Texas, United States
View Trial DetailsNCT02068885
Body Weight, Cardiovascular Disease
Framingham, Massachusetts, United States
View Trial DetailsNCT02806700
Cardiovascular Disease, Cardiovascular Diseases
Philadelphia, Pennsylvania, United States
View Trial Details